Hohimer Wealth Management LLC Purchases New Holdings in Incyte Corporation $INCY

Hohimer Wealth Management LLC purchased a new position in shares of Incyte Corporation (NASDAQ:INCY) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 55,100 shares of the biopharmaceutical company’s stock, valued at approximately $6,686,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INCY. Fiduciary Financial Advisors acquired a new position in Incyte during the second quarter worth $26,000. Provenance Wealth Advisors LLC bought a new position in Incyte in the third quarter valued at $33,000. Continuum Advisory LLC acquired a new stake in Incyte in the 2nd quarter valued at $36,000. Latitude Advisors LLC acquired a new stake in Incyte in the 3rd quarter valued at $39,000. Finally, Quantbot Technologies LP acquired a new stake in Incyte in the 2nd quarter valued at $52,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the transaction, the insider directly owned 183,200 shares in the company, valued at $23,002,592. The trade was a 5.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares in the company, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 14,053 shares of company stock worth $1,726,519 over the last 90 days. 16.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. UBS Group set a $152.00 price target on shares of Incyte in a research report on Friday, October 30th. BMO Capital Markets restated a “market perform” rating on shares of Incyte in a report on Tuesday, October 27th. Canaccord Genuity Group initiated coverage on Incyte in a report on Thursday, August 20th. They issued a “buy” rating and a $152.00 price objective for the company. Weiss Ratings downgraded Incyte from a “buy (b)” rating to a “hold (c)” rating in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating on shares of Incyte in a report on Tuesday, October 27th. Eleven analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $132.86.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Incyte Stock Performance

NASDAQ:INCY opened at $119.65 on Monday. The stock has a market capitalization of $24.39 billion, a PE ratio of 63.64, a P/E/G ratio of 4.36 and a beta of 0.78. Incyte Corporation has a 1-year low of $89.25 and a 1-year high of $132.60. The firm has a fifty day simple moving average of $119.62 and a 200 day simple moving average of $108.51.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.93) by $0.33. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.26 earnings per share. On average, equities analysts predict that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.

Incyte Profile

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.